LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer

Histone deacetylase inhibitors (HDACi) are identified as novel therapeutic agents, however, recent clinical studies suggested that they are marginally effective in treating triple negative breast cancer (TNBC). Here, we show that first-in-class Leukemia Inhibitory Factor Receptor (LIFRα) inhibitor E...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mengxing, Viswanadhapalli, Suryavathi, Santhamma, Bindu, Pratap, Uday P., Luo, Yiliao, Liu, Junhao, Altwegg, Kristin A., Tang, Weiwei, Liu, Zexuan, Li, Xiaonan, Ebrahimi, Behnam, Yan, Hui, Zou, Yi, Konda, Swapna, Sareddy, Gangadhara R., Xu, Zhenming, Chen, Yidong, Rao, Manjeet K., Brenner, Andrew J., Kaklamani, Virginia G., Tekmal, Rajeshwar R., Ahmed, Gulzar, Raj, Ganesh V., Nickisch, Klaus J., Nair, Hareesh B., Vadlamudi, Ratna K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556368/
https://www.ncbi.nlm.nih.gov/pubmed/34716410
http://dx.doi.org/10.1038/s42003-021-02741-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556368/
https://www.ncbi.nlm.nih.gov/pubmed/34716410
http://dx.doi.org/10.1038/s42003-021-02741-7

Ejemplares similares